About AI Proteins
AI Proteins is a private company based in Boston, Massachusetts, incorporated in 2021 in Delaware. It has reported $24,616,003 raised in three offerings on Form D since January 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Apr 4, 2024 | $4,995,000of $10.0M target | 8 | $624K | DebtRule 506(b) | Form D ↗ |
| Jul 21, 2023 | Aug 4, 2023 | $8,300,000of $10.0M target | 7 | $1.1M | DebtRule 506(b) | Form D ↗ |
| Jan 11, 2022 | Jan 21, 2022 | $11,321,003of $18.2M target | 38 | $297K | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $24,616,003 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on AI Proteins's Form D filed Apr 4, 2024.
Earlier filings also listed Mark Alles (director, last listed Aug 2023), William McKee (director, last listed Jan 2022), Namandje Bumpus (director, last listed Jan 2022), Marc Cohen (executive officer and director, last listed Jan 2022), Geoff Meyerson (director, last listed Jan 2022), Elena Prokupets (director, last listed Jan 2022), Dominique Verhelle (director, last listed Jan 2022) and Carl Novina (director, last listed Jan 2022).